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With age, individuals acquire somatic mutations in their hematopoietic stem and progenitor cells (HSPCs), which produce the various blood cell lineages, including monocytes, mast cells, neutrophils, megakaryocytes, B cells, and T cells ([@bib33]). Some of these mutations can promote the competitive advantage and expansion of specific leukocyte clones in a process called clonal hematopoiesis (CH) ([@bib33]). The presence of CH in the context of aging is called age-related clonal hematopoiesis (ARCH), which describes the existence of any stem cell subpopulation or clone ([@bib15]). When these clones harbor mutations in preleukemic genes at a variant allele frequency (VAF) of 2% or greater, they define a novel condition called clonal hematopoiesis of indeterminate potential (CHIP), in which seemingly healthy individuals are at an increased risk of developing hematological disease ([@bib34]). Depending on the depth of DNA sequencing, CHIP can be detected in as high as 95% of adults, making it a very common but poorly understood phenomenon ([@bib84]). Epigenetic regulators, including the *Tet methylcytosine dioxygenase 2* (*TET2*), *DNA methyltransferase* 3A (*DNMT3A*), and *associated sex combs-like 1* (*ASXL1*) genes, are commonly mutated in CHIP ([@bib33]). In leukemia, mutations in these genes are often present in HSPCs early in the development of hematological malignancy ([@bib36]). However, the scope of the pathogenesis and the clinical implications of CHIP have not yet been fully characterized.

Remarkably, recent studies have also linked CHIP to an increased risk of cardiovascular and cerebrovascular disease (CVD), including atherosclerosis, myocardial infarction, and ischemic stroke ([@bib34], [@bib35]). This correlation suggests that preleukemic mutations in hematopoietic lineages can predispose individuals to CVD and that CVD may be an important clinical manifestation of CHIP. Recently, CHIP has been linked to inferior outcomes in heart failure patients ([@bib25]). The magnitude of the VAF correlated with the severity of the clinical outcome, suggesting an important role for the expansion of clones containing CHIP-associated mutations in CVD pathogenesis ([@bib25]). The effects of CHIP-associated mutations on atherosclerosis and heart failure, but not cerebrovascular disease, have been confirmed in mouse models. Transplantation of *Tet2*-deficient bone marrow (BM) into the *Low-density lipoprotein receptor* (*Ldlr*)-deficient mouse model of atherosclerosis susceptibility accelerated atherosclerosis via pro-inflammatory macrophages ([@bib29]; [@bib35]). Similarly, mice transplanted with *Tet2*-deficient BM exhibited worse cardiac remodeling in heart failure models ([@bib63], [@bib64]). Expression of mutant *Janus kinase 2* (*JAK2*), which is also mutated in CHIP, in myeloid cells exacerbated heart failure by promoting inflammation and cardiac remodeling ([@bib65]). Notably, transplant of *Tet2*-deficient BM into non-irradiated wild-type mice increased fibrosis and hypertrophy, indicating that loss of *Tet2* in BM may not only exacerbate existing CVD but may also directly cause CVD ([@bib79]).

CHIP also affects the outcomes of cardiac procedures, implicating it in multiple manifestations of CVD. The presence of CHIP-associated mutations increased all-cause mortality after transcatheter aortic valve implantation ([@bib51]). Remarkably, CVD is also observed in patients undergoing hematopoietic stem cell transplantation (HSCT). Similar to CHIP patients, HSCT patients exhibit coronary heart disease and heart failure ([@bib6]; [@bib7]). Notably, HSCT patients developing CVD tended to be older, and conditioning regimens included total body irradiation, chest irradiation, and anthracycline treatment ([@bib8]). It is not yet known if CVD in HSCT patients can be attributed to CHIP-associated mutations. However, if so, it would suggest that HSPCs carrying CHIP-associated mutations have intrinsic pathogenic features that enable them to promote CVD in a new environment. HSPCs bearing CHIP-associated mutations can preserve cell-autonomous features under stressful conditions, such as transplantation, but additional studies are needed to investigate this possibility in the context of CVD ([@bib85]).

Collectively, these studies support a broad role for CHIP-associated mutations in CVD, affecting multiple stages in its pathogenesis. They indicate that CHIP is an important novel risk factor for CVD in seemingly healthy individuals, but much remains unknown regarding the mechanisms underlying its contributions to CVD. The breadth of CHIP\'s effects is consistent with the diverse functions of the hematopoietic cell types, many of which play significant roles in CVD ([@bib70]). The presence of CHIP-associated mutations in HSPCs suggests that these mutations have the potential to influence multiple cell types involved in CVD as well as cause hematological malignancy, providing a possible link between these pathologies ([Figure 1](#fig1){ref-type="fig"}). However, these processes are only beginning to be explored. It is not yet known if mutant HSPCs or their differentiated progeny contribute to or cause CHIP-associated CVD. Two important unanswered questions regarding CHIP are (1) whether CHIP-associated mutations alter the functions of multiple hematopoietic lineages and (2) whether CHIP-associated CVD and hematological malignancies represent a common disease process. The objective of this review is to discuss support for these notions and to provide a rationale for their further investigation.Figure 1Putative Contributions of Hematopoietic Lineages to CVD and Potential Links between CHIP-Associated CVD and Hematological DiseasesHSPCs give rise to the many hematopoietic cell lineages. CHIP mutations (yellow star) in HSPCs are transmitted to mature hematopoietic lineages, many of which play roles in the different stages of CVD by modulating the inflammatory response. The roles of CHIP-associated mutations in these different cell types have not yet been explored. CHIP-associated mutations have been linked to both CVD and hematological malignancy, but it is not yet known if these two pathologies represent a common disease process or distinct events. LT-HSPCs, long-term HSPCs; ST-HSPCs, short-term HSPCs; CLPs, common lymphoid progenitors; CMPs, common myeloid progenitors; MC, mesenchymal cell; EC, endothelial cell.

CVD Is a Complex Process Involving Multiple Cell Types and Stages {#sec1.2}
-----------------------------------------------------------------

CVD is a dynamic process involving multiple stages ([@bib45]; [@bib47]). Atherosclerosis is characterized by the accumulation of lipid plaques in vessels, and its progression increases the risk for myocardial infarction, which can cause heart failure ([@bib69]). Importantly, many types of leukocytes play key and distinct roles throughout CVD ([@bib69], [@bib70]). During the stages of CVD, these cell types interact to promote either inflammation or repair ([@bib71]; [@bib74]). The most abundant leukocytes in atherosclerotic lesions, macrophages are involved in both the promotion and regression of inflammation ([@bib69]). Neutrophils modulate monocyte recruitment and oxidative stress, while platelets facilitate monocyte entry into plaques and promote thrombus formation ([@bib69]). B cells and T cells can either promote or inhibit atherosclerosis ([@bib69]). In heart failure, B cells influence the myocardial leukocyte pool and affect myocardial mass and left ventricular contractility ([@bib3]). CD8^+^ T cells attenuate inflammation and promote scar formation, and their loss increases the numbers of neutrophils and macrophages, indicating cooperation among hematopoietic lineages in CVD ([@bib32]). Mast cells destabilize plaques, attract monocytes and neutrophils from the BM to the injured heart, and affect fibrosis ([@bib39]; [@bib40]; [@bib70]). Neutrophils also aid in macrophage polarization into distinct subtypes, highlighting the complex contributions of different hematopoietic cell subtypes to CVD ([@bib70]). The involvement of multiple hematopoietic lineages throughout the various stages of CVD provides many opportunities for CHIP to influence CVD; however, the roles of these cell types in the context of CHIP are only beginning to be investigated.

Inflammation May Be a Key Mechanism for CHIP-Associated CVD {#sec1.3}
-----------------------------------------------------------

Many of the hematopoietic lineages contribute to the inflammatory response, and recent studies suggest that inflammation may play a critical role in the pathogenesis of CHIP-associated CVD ([@bib29]; [@bib63], [@bib64]; [@bib79]). The accelerated atherosclerosis observed in *Ldlr*-deficient mice transplanted with *Tet2*-deficient BM is attributed to pro-inflammatory macrophages secreting increased interleukin-1β (IL-1β) via NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3), a key inflammatory mediator that cleaves IL-1β into its active form ([@bib29]). TET2 regulates the expression of NLRP3 and IL-1β as well as NLPR3-mediated cleavage of IL-1β; consequently, *Tet2* inactivation increases IL-1β levels ([@bib29]). Elevated expression of CXC motif chemokine ligand (Cxcl) 1, Cxcl2, Cxcl3, platelet factor 4 (Pf4), and IL-6 was also observed, indicating that the inflammatory response in CHIP-associated CVD may be complex ([@bib35]). In heart failure, loss of *Tet2* prevented recovery and promoted inflammation, indicating that inflammation may contribute to CHIP-associated CVD in different disease contexts and stages ([@bib63], [@bib64]). Inhibition of the NLRP3 inflammasome reduced fibrosis and hypertrophy and normalized cardiac functions, suggesting that macrophages play a similar role in both atherosclerosis and heart failure in mice ([@bib64]). These results are consistent with previous studies showing that TET2 prevents the expression of inflammatory genes and that tumor necrosis factor alpha (TNF-α) promotes the expansion of *Tet2*-deficient HSPCs *in vitro* ([@bib21]; [@bib2]). Similarly, inactivation of *Dnmt3a* in mice promotes mast cell activation, supporting the notion that inflammation may be a key mechanism underlying CHIP-associated CVD ([@bib43]). In a model of CHIP-associated CVD in which mice transplanted with *Tet2*- or *Dnmt3a*-deficient BM cells were stimulated with angiotensin II, loss of either *Tet2* or *Dnmt3a* caused cardiac and renal dysfunction, but differences in CVD kinetics and cytokine and chemokine expression were detected ([@bib63]). As the inflammatory response in CVD involves a balance of resolving and non-resolving factors, the increased inflammation due to CHIP may impede the ability to effectively resolve inflammation, leading to an exacerbation of CVD ([@bib74]). Notably, inflammation plays a differential role in subtypes of heart failure ([@bib67]). Consequently, CHIP may have distinct implications for different types of heart failure.

As *Tet2* loss promotes a pro-inflammatory macrophage phenotype, it is possible that specific subpopulations of macrophages exacerbate CHIP-associated CVD. Macrophages consist of diverse subpopulations and exhibit distinct functions during the different stages of CVD pathogenesis and progression ([@bib10]; [@bib56]). These changes in cell-type subpopulations and the stage of pathogenesis may have significant implications for signaling. For example, while inhibition of IL-1β reduces atherosclerotic plaque size, it is protective at later stages of atherosclerosis ([@bib30]). While IL-1 receptor signaling appears to be important for CHIP-associated atherosclerosis in mice, it remains unclear whether CHIP-associated CVD is exclusively IL-1-dependent or whether additional inflammatory pathways contribute. Elevated serum IL-6, IL-8, monocyte chemoattractant protein 1 (MCP1 or CCL2), and TNF-α have been reported in CHIP patients, supporting a complex or heterogeneous inflammatory response ([@bib19]). Notably, IL-6 deficiency reduces the risk of CHIP-associated CVD, indicating a key role for IL-6 ([@bib11]). The cell types responsible for producing these other cytokines are not yet known. Collectively, these studies suggest that inflammation and macrophages play critical roles in CHIP-associated CVD; however, multiple inflammatory pathways and hematopoietic cell types may promote pathogenesis ([Table 1](#tbl1){ref-type="table"}).Table 1Significant Studies Investigating CHIP-Associated CVDStudyHematopoietic Cell TypesKey Findings[@bib34]N/AIncreased risks of hematologic cancer, all-cause mortality, coronary heart disease, and ischemic stroke were observed in individuals with CHIP. Mutations in *DNMT3A*, *TET2*, and *ASXL1* constituted most of the CHIP variants in this study.[@bib53]Mast cellsTET2 regulated mast cell differentiation. Upon IgE and antigen stimulation, *Tet2*-deficient mast cells produced reduced levels of the mast cell cytokines IL-6, TNF-α, and IL-13.[@bib21]MacrophagesTET2 prevented inflammation and was highly expressed during macrophage differentiation. *Tet2* loss led to increased *Il-1β*, *Il-6*, and *Arginase 1* during later stages of LPS stimulation of BM-derived macrophages.[@bib29]MacrophagesIn *Ldlr*-deficient mice transplanted with *Tet2*-deficient BM cells, pro-inflammatory *Tet2*-deficient macrophages increased the secretion of IL-1β via the NLRP3 inflammasome. TET2 regulated expression of the NLRP3. inflammasome. Inhibition of the NLRP3 inflammasome impaired the growth of atherosclerotic plaques.[@bib35]N/AIncreased risks of coronary heart disease, coronary-artery calcification, and early-onset myocardial infarction were observed in individuals with CHIP. *Ldlr*-deficient mice transplanted with BM from *Tet2*-deficient mice exhibited accelerated atherosclerosis. Increased RNA and protein expression of IL-1β, IL-6, CXCL1, CXCL2, CXCL3, and PF-4 was measured in these transplanted mice. Increased expression of IL-8 was detected in the plasma of individuals with CHIP.[@bib43]Mast cellsDNMT3A attenuated mast cell responses to acute and chronic stimuli. Loss of *Dnmt3a* was associated with increased sensitivity to stimuli, increased cytokine release, and enhanced degranulation capacity.[@bib2]HSPCsChronic TNF-α exposure promoted a clonogenic advantage for murine *Tet2*-deficient and human *TET2*-mutant HSPCs *in vitro*. The expansion of these HSPCs coincided with resistance to apoptosis and myeloid skewing. This study suggests an important role for HSPCs carrying CHIP-associated mutations, in addition to mature hematopoietic lineages.[@bib14]N/APatients with CHIP-associated mutations in *TET2* or *DNMT3A* exhibited different hematopoietic lineages. *TET2* mutations correlated with greater myeloid populations and no multipotent lineages, whereas *DNMT3A* mutations coincided with multipotent lineages. The kinetics of clonal expansion differed with distinct CHIP-associated mutations.[@bib16]HSPCs and myeloid cellsIncreased *Tet2*-deficient mature myeloid cells and HSPCs were detected in response to inflammatory stress, leading to enhanced production of inflammatory cytokines, such as IL-6. The long non-coding RNA *Morrbid* was increased in response to IL-6. Inhibition of SHP2 or STAT3 or loss of *Morrbid* inhibited CH of *Tet2*-deficient HSPCs.[@bib63]MacrophagesIn response to angiotensin II, mice lacking either *Tet2* or *Dnmt3a* developed cardiac hypertrophy, cardiac and renal fibrosis, and reduced cardiac function. The kinetics of clonal expansion differed in *Tet2*- and *Dnmt3a*-deficient mice. Increased expression of *Il-1β*, *Il-6*, and *Ccl5* was detected in an LPS-stimulated *Tet2*-deficient macrophage cell line, whereas elevation of *Cxcl1*, *Cxcl2*, *Il-6*, and *Ccl5* was observed in an LPS-stimulated *Dnmt3a*-deficient macrophage cell line.[@bib64]Macrophages*Tet2*-deficient hematopoietic or myeloid cells exacerbated cardiac remodeling and function and correlated with increased IL-1β expression in transaortic constriction and chronic ischemia models of heart failure. Inhibition of the NLRP3 inflammasome improved cardiac measurements and alleviated heart failure development.[@bib82]NeutrophilsCH for *JAK2*^*V617F*^, the most common driver of myeloproliferative neoplasm, correlated with an increased occurrence of thrombosis. Mice expressing *JAK2*^*V617F*^ exhibited increased NET formation and thrombosis, which were alleviated by the JAK2 inhibitor ruxolitinib.[@bib19]N/AElevated expression of IL-6, MCP1/CCL2, and TNF-α was detected in individuals with CHIP.[@bib25]N/APatients with CHIP often had a history of hypertension. Mutations in *TET2* or *DNMT3A* were associated with worse heart failure outcomes.[@bib54]N/AIn response to TNF-α stimulation of endothelial cells, increased methylation was detected at sites in the *ACE* promoter in a *DNMT3A*- and *DNMT3B*-dependent manner.[@bib65]Myeloid cellsMice with myeloid expression of the *JAK2*^*V617F*^ mutation demonstrated increased cardiac inflammation and dysfunction after permanent left anterior descending artery ligation and transverse aortic constriction.[@bib11]N/AIndividuals with large CHIP clones (VAF \> 10%) that also carry an *IL-6 receptor* p.Asp358Ala mutation exhibited fewer CVD events.[@bib51]T cells and myeloid cellsPatients with aortic valve stenosis undergoing transcatheter aortic valve implantation and carrying *TET2* or *DNMT3A* mutations experienced worse outcomes. Patients with *TET2* mutations showed increased pro-inflammatory non-classical monocytes, whereas patients with *DNMT3A* mutations exhibited pro-inflammatory T cell polarization.[@bib78]PlateletsMutations in different CHIP-associated genes were linked to differences in platelet number and risk of thrombosis and bleeding.[@bib79]Myeloid cellsTransplantation of *Tet2*-deficient BM cells into non-irradiated recipient mice resulted in cardiac dysfunction, hypertrophy, and fibrosis. Macrophages isolated from the heart exhibited upregulation of cytokines, cytokine receptors, and interferon-related genes and downregulation of genes involved in regulation of cell differentiation and neurogenesis.[^1]

Additional Hematopoietic Lineages May Contribute to CHIP-Associated CVD {#sec1.4}
-----------------------------------------------------------------------

In addition to macrophages, many other hematopoietic lineages participate in CVD. Consequently, they may be altered by CHIP and may modify the pathogenesis and outcomes of CHIP-associated CVD. For example, perivascular mast cells release pro-inflammatory cytokines, such as IL-6 and interferon-γ, and facilitate atherosclerotic plaque destabilization ([@bib13]; [@bib39]; [@bib68]). Loss of *Dnmt3a* in mast cells increases cytokine release, enhances degranulation capacity, and increases sensitivity to stimuli ([@bib43]). Levels of mast cells correlate with an increased risk of adverse cardiovascular (CV) events, supporting an important clinical role for mast cells in CVD ([@bib80]). Consequently, CHIP-associated genes may also promote the inflammatory response in CVD via mast cells. CHIP-associated mutations were recently associated with differential effects on platelet number and risk for thrombosis and bleeding, and pro-inflammatory lymphoid lineages have been detected in CHIP patients with CVD ([@bib51], [@bib78]). Furthermore, individuals exhibiting CH for the *JAK2*^*V617F*^ mutation have an increased occurrence of thrombosis associated with neutrophil extracellular traps (NETs), indicating another hematopoietic lineage that can contribute to CHIP-associated CVD ([@bib82]). In this context, this increased risk of thrombosis does not appear to be associated with CV risk factors, inferring that CHIP alone may increase the risk of CVD. Additional studies are needed to elucidate the functions of these different hematopoietic cell types in CHIP-associated CVD.

Differences in the distribution and functions of hematopoietic lineages may influence the manifestation of inflammation at different stages of pathogenesis and may have important implications for disease heterogeneity and the treatment of CHIP-associated CVD. For example, mutations in *TET2* may lead to an accumulation of pro-inflammatory macrophages, whereas mutations in *JAK2* and *DNMT3A* may be characterized by prominent responses by neutrophils, mast cells, and T cells ([Figure 2](#fig2){ref-type="fig"}). These changes may influence the ability to resolve inflammation. Single-cell RNA sequencing has identified functional subtypes of these cell types, further complicating the potential implications of CHIP-associated mutations ([@bib81]). In addition, cell-type-specific functions of the NLRP3 inflammasome have been reported in myocardial infarction, providing an opportunity for multiple cell types to modulate this pathway ([@bib72]).Figure 2Different CHIP-Associated Mutations May Have Differential Effects on the Distinct Hematopoietic Lineages That Contribute to CVD(A) Many different hematopoietic lineages contribute to CVD. In atherosclerosis, pro-inflammatory macrophages (purple) accelerate plaque formation. Mast cells (blue) and neutrophils (green) promote thrombosis via IL-6 and neutrophil extracellular traps, respectively. B cells (brown) secrete antibodies and cytokines. Polarized T cells (orange) facilitate inflammation. All of these cell types have the potential to carry CHIP-associated mutations (yellow star) and to alter CHIP-associated CVD.(B) Different CHIP-associated mutations may influence the cell types involved in and the pathogenesis of CHIP-associated CVD at different stages. Loss of *TET2*, *JAK2*, and *DNMT3A* has been associated with macrophages, neutrophils, and mast cells and T cells, respectively.

Different CHIP-associated genes differentially affect the various hematopoietic lineages, biasing the distribution of these lineages toward specific cell populations. For example, inactivation of the *Tet2* gene promotes a myeloid shift and can alter mast cell differentiation and proliferation ([@bib53], [@bib14]). In CHIP patients undergoing transcatheter aortic valve implantation for degenerative aortic valve stenosis, *DNMT3A* mutations were associated with pro-inflammatory T cells, whereas *TET2* mutations correlated with pro-inflammatory non-classical monocytes, suggesting that different mutations may influence the hematopoietic lineages that can contribute to CHIP-associated CVD ([@bib51]). While both the T cells and monocytes were pro-inflammatory, it is not yet known if they promote inflammation via a common mechanism. CHIP-associated mutations have been detected in lymphoid lineages; however, the implications of lymphoid lineages for CHIP-associated CVD have not yet been explored ([@bib12]; [@bib14]). Significantly, the penetrance of CHIP-associated mutations in different hematopoietic lineages depends on the specific gene carrying the mutation. In CHIP patients carrying single *DNMT3A* mutations, 41% of the peripheral mononuclear cells (PMNs) were multipotent, while 36% and 23% were myeloid and myelolympho-B cells, respectively. The VAFs in the myelolympho-B and multipotent lineages were 10% or greater, while the VAF in the myeloid lineage was less than 10% ([@bib14]). In contrast, CHIP patients bearing single *TET2* mutations exhibited 54% of PMNs from the myeloid lineage and 46% from the myelolympho-B lineage. The VAFs were approximately 10% in both the myeloid and myelolympho-B lineages ([@bib14]). In HSCT donors with CHIP and their recipients, granulocytes, monocytes, B cells, and T cells demonstrated mean VAFs of 0.08, 0.083, 0.028, and 0.007, respectively ([@bib12]). These studies support the notion that different CHIP-associated mutations may differentially affect the distribution of the affected hematopoietic cell types and their functions in CVD. These mutation-specific and cell-type differences may have important implications for the clinical presentations, prognoses, and latencies of and the therapeutic development for CHIP-associated CVD.

Epigenetic Regulators May Drive the Distributions of Hematopoietic Lineages and May Contribute to CHIP-Associated CVD {#sec1.5}
---------------------------------------------------------------------------------------------------------------------

As epigenetic regulators are frequently mutated in CHIP, epigenetic modulation may contribute to the pathogenesis of CHIP-associated CVD ([@bib35]). Mutations in and loss of CHIP-associated epigenetic regulators in HSPCs differentially affect the resulting hematopoietic lineages, supporting an important role for stem cells in the pathogenesis of CHIP-associated diseases ([@bib14]). Inactivation of *Tet2* or *Asxl1* in HSPCs leads to more myeloid phenotypes, whereas loss of *Dnmt3a* in these cells causes both myeloid and lymphoid disease, indicating that these epigenetic regulators can affect the availability of hematopoietic lineages ([@bib1]; [@bib44]; [@bib52]). However, the effects of these CHIP-associated genes on the distribution of hematopoietic lineages, disease severity, latency, and penetrance of CHIP-associated CVD are not yet known.

In addition to skewing the differentiation of HPSCs, epigenetic regulation may also influence the contributions of mature hematopoietic cell types to CHIP-associated CVD as epigenetic regulation contributes to atherosclerosis, heart failure, and inflammation ([@bib61]). For example, differences in DNA methylation detected in atherosclerotic and normal aortas may correlate with disease progression, and loss of histone deacetylase 3 exacerbates atherosclerosis ([@bib87]; [@bib76]). Exercise can modulate epigenetic factors in a model of atherosclerosis, indicating that epigenetic differences may alter the ability to respond to environmental influences that affect CVD ([@bib28]). Many of these studies report epigenetic changes in endothelial cells or vascular smooth muscle cells; however, less is known about the effects of epigenetic modification in hematopoietic lineages on CVD.

Many opportunities exist for epigenetic regulators to alter the functions of mature hematopoietic lineages. For example, TET2 regulates the expression of NLRP3 and IL-1β ([@bib29]). Previously, our group demonstrated that the long-noding RNA *Morrbid* is increased in *Tet2*-deficient cells challenged with lipopolysaccharide and that loss of *Morrbid* ameliorates the inflammatory phenotype of *Tet2*-deficient cells, broadening the impact of epigenetic regulation in CH and suggesting that multiple epigenetic regulators may be important in CH ([@bib16]). Notably, *Dnmt3a* is upregulated in response to altered blood flow and can modulate the expression levels of angiotensin-converting enzyme (ACE), which regulates blood pressure, in endothelial cells in response to inflammation ([Figure 4](#fig4){ref-type="fig"}) ([@bib88]; [@bib54]). Cardiac mast cells also secrete renin, an upstream regulator of angiotensin, and the release of renin can contribute to various manifestations of CVD ([@bib48]; [@bib58]). These observations suggest a role for mast cells in blood pressure regulation and the ability of CHIP-associated genes to influence blood pressure. Notably, CHIP patients more frequently exhibit hypertension; however, the mechanisms are not understood ([@bib25]). These epigenetic changes may modify the distributions and functions of the hematopoietic lineages that modulate CHIP-associated CVD. These studies suggest that there are multiple possible mechanisms by which epigenetic factors can affect CHIP-associated CVD.

Inflammation and CVD Can Influence Hematopoiesis {#sec1.6}
------------------------------------------------

While epigenetic regulation may impact the hematopoietic lineages contributing to CHIP-associated CVD, inflammation may also shape the distributions of these cell types as cytokines play a critical role in regulating hematopoiesis ([@bib29]). Associated with stresses, such as infection, inflammation mobilizes HSPCs and influences differentiation patterns to bolster the immune system. For example, the NLRP3 inflammasome, interferon-γ, and IL-1 promote the mobilization of HSPCs ([@bib22]; [@bib42]; [@bib50]). However, the timing of the inflammatory response may be critically important as chronic inflammation is associated with HSPC exhaustion and damage ([@bib17]; [@bib57]). In addition, different cytokines may exert differential effects depending on the context and the other inflammatory mediators present, both of which may be altered by CHIP ([@bib50]). We and others have shown that *Tet2*-deficient HSPCs secrete cytokines and that inflammation promotes the expansion of these HSPCs, suggesting that, in addition to mature hematopoietic lineages, HSPCs carrying CHIP-associated mutations may actively contribute to the inflammation observed in CHIP ([@bib2]; [@bib16]). These findings are consistent with the observation that transplantation of *Tet2*-deficient BM is sufficient to cause CHIP-associated CVD ([@bib79]).

In addition to promoting the expansion of clones carrying CHIP-associated mutations, inflammation can also alter the BM microenvironment ([@bib41]). Inflammation and the BM microenvironment change with age, influencing the context in which CHIP-associated inflammation occurs ([@bib31]; [@bib38]). As loss of either *Tet2* or *Dnmt3a* is implicated in inflammation, HSPCs carrying CHIP-associated mutations and/or the presence of CHIP-associated CVD may promote an inflammatory state that can alter the BM microenvironment, leading to more permanent changes in hematopoiesis and a propensity to promote HSPC damage. It has been proposed that, in CVD, mature hematopoietic cells and HSPCs create a reinforcing feedforward system in which the inflammation from one fuels the other ([@bib18]). This notion may also apply in CHIP. Elevated levels of cytokines and chemokines have been detected in the serum of CHIP patients, indicating that these patients exhibit systemic inflammation ([@bib19]). However, changes in the BM microenvironment of patients with CHIP or CHIP-associated CVD have not yet been investigated.

CVD can also increase hematopoietic activity, identifying a means of communication between the CV and hematopoietic systems ([@bib4], [@bib5]). Ischemic stroke and atherosclerosis stimulate HSPCs ([@bib20]; [@bib77]). HSCTs have been evaluated to treat infarction and ischemic damage as HSPCs can home to injured heart tissues ([@bib37]; [@bib75]). In addition, exercise alleviates CV inflammation by modulating hematopoiesis ([@bib28]). The existence of these effects implies the possibility of a system in which the hematopoietic and CV systems may reciprocally influence disease progression in CHIP. Hypertension leads to unstable atherosclerotic lesions due to stimulation of hematopoiesis ([@bib5]). Remarkably, stress-induced hypertension causes depletion of HSPCs and reduction of osteoblasts and sinusoidal endothelial cells in the BM microenvironment, suggesting that hypertension may also promote remodeling of the BM microenvironment ([@bib5]). As *DNMT3A* can regulate ACE expression, mutations in DNMT3A may lead to an elevation in blood pressure that modulates the BM microenvironment ([Figure 4](#fig4){ref-type="fig"}) ([@bib54]). It remains to be seen if loss of *DNMT3A* function in hematopoietic cells can dysregulate ACE expression. Importantly, as CHIP is predominant in older individuals, CHIP-associated diseases will also occur in an older CV system, which is characterized by increased cardiac leukocytes, including monocyte-derived cardiac macrophages, granulocytes, and CD8+ T cells ([@bib70]). These aging-associated changes in the CV system may also have important implications for CHIP-associated CVD. Collectively, these observations raise the possibility that CHIP-associated mutations may trigger a cascade of events that alters hematopoiesis and/or the BM microenvironment via inflammation and cardiac physiology.

CHIP-Associated CVD and Hematological Malignancy May Represent a Progression of the Same Disease Process {#sec1.7}
--------------------------------------------------------------------------------------------------------

The communication between the CV and hematopoietic systems supports a potential interaction between these systems in CHIP-associated CVD. Increased reports of CVD in patients with hematological malignancies further suggest that these pathologies may coexist or represent a spectrum of clinical presentations. For example, patients with acute leukemia exhibit increased left ventricle masses and volumes and decreased global longitudinal strain before chemotherapy, demonstrating an inherent CV deficit in patients with hematological malignancies ([@bib9]). In addition, patients with hematological malignancies can exhibit CVD and CV toxicities to chemotherapy, and these toxicities appear to increase with age, suggesting that these patients may also be more susceptible to CV injury ([@bib24]; [@bib49]). It is currently unclear if CHIP contributes to these pathologies; however, a more thorough understanding of the role of CHIP in CVD may help identify patients who will be more susceptible to the development of CVD and CV toxicities. An increased incidence of thrombosis associated with *JAK2^V617F^* mutations was observed in patients with myeloproliferative neoplasms, demonstrating the possibility that cancer and CVD can coexist ([@bib82]). Patients with myeloproliferative disease and increased thrombotic events also have an increased risk of secondary cancers ([@bib23]). Together, these studies support a potential link between CVD and oncogenesis. However, while CHIP is associated with an increased risk of both hematological malignancies and CVD, it is not yet known if these pathologies occur in the same individuals, if they represent a spectrum of disease progression, or if they are distinct events. Consequently, there are several possible outcomes associated with CHIP ([Figure 3](#fig3){ref-type="fig"}). Individuals may carry CHIP-associated mutations, but the mutant clones maintain their size and fail to contribute to pathology. If the mutant clones expand, they may lead to CVD, hematological malignancy, or both. Longitudinal studies of CHIP patients are needed to fully understand the progression of CHIP-associated diseases and the contributions of different clinical presentations.Figure 3Potential Outcomes for the Evolution of CHIP-Associated CVD and Hematological Malignancy from HSPCs Carrying CHIP-Associated MutationsMutant clones (red) can expand or be maintained. As CHIP has been linked to both CVD and hematological malignancy, expansion of mutant clones may lead to CVD alone, hematological malignancy alone, or a combination of CVD and hematological malignancy. The acquisition of additional mutations (green) is usually needed to promote the evolution of CH to hematological malignancy and often requires an inciting event (lightning bolt). It is not yet known if CVD and hematological malignancy represent progression of the same disease process or distinct events. However, the inflammation from CHIP-associated CVD may drive the acquisition of additional mutations and the progression to hematological malignancy.

Commonalities exist between the pathogenesis of CVD and cancer, including cell proliferation, apoptosis, inflammation, leukocyte infiltration, and remodeling of the extracellular matrix ([@bib47]; [@bib73]). These similarities and the ability of the CV and hematological systems to communicate may allow these conditions to coexist and evolve simultaneously. In particular, inflammation may serve as a unifying driver of pathogenesis for CVD and hematological malignancy as it is an important factor in both of these pathologies. TNF-α promotes survival of HSPCs and myeloid regeneration, and IL-6 facilitates the development of chronic myeloid leukemia, indicating that inflammation can promote leukemogenesis ([@bib59]; [@bib83]). Additional mutations are often required for the development of leukemia and are obtained during clonal evolution of HSPCs ([@bib62]). In preleukemic scenarios, inflammation can promote genotoxic stress and disease progression, suggesting that inflammation may create an environment in which HSPCs carrying CHIP-associated mutations can acquire additional mutations and facilitate leukemogenesis ([@bib86]).

A potential explanation for the coexistence of CHIP-associated CVD and hematological malignancy is that raised blood pressure from increased expression of ACE or renin or cytokines from HSPCs or mature hematopoietic lineages may act as selective pressures that facilitate the remodeling of the BM microenvironment ([Figure 4](#fig4){ref-type="fig"}). Interferon-γ from the BM can reduce the size of atherosclerotic plaques in *Ldlr*-deficient mice, indicating that signals from the BM can modulate CVD ([@bib55]). In addition, the vascular niche, a component of the BM microenvironment, plays an important role in hematopoiesis and leukemogenesis; however, it is not known if CHIP-associated CVD alters the vascular niche ([@bib27]; [@bib66]). If so, changes in the vascular niche due to CHIP-associated CVD may link CVD and hematological malignancy in CHIP. These changes in the BM microenvironment may create a biological context conducive to leukemogenesis and genotoxic stress ([Figure 4](#fig4){ref-type="fig"}). It is also compelling to consider the ways in which changes in clonal dynamics may modify the CVD presentation. Further studies are needed to investigate these interactions and the potential co-occurrence of CHIP-associated CVD and hematological malignancies. Collectively, these studies suggest the existence of a significant relationship between the CV and hematopoietic systems and underscore the importance of studying the consequences of this relationship for CHIP.Figure 4Model for Altered Hematopoiesis and the Development of Hematological Malignancy in Response to CHIP-Associated CVDLoss of CHIP-associated genes is associated with an increased release of cytokines from HSPCs and mature hematopoietic lineages. These cytokines may promote expansion of the mutant clones and CVD. Increased inflammation and blood pressure are associated with CVD. Both of these changes can alter the BM microenvironment, which contributes to hematopoiesis. These stresses on the BM microenvironment may aberrantly alter hematopoiesis to promote hematological malignancy and may create genotoxic stress that facilitates the acquisition of additional mutations. MC, mesenchymal cell; EC, endothelial cell.

CHIP Has Implications for the Treatment of CVD {#sec1.8}
----------------------------------------------

Current studies indicate anti-inflammatory agents, such as inhibitors of IL-1β and the NLRP3 inflammasome, as potential treatments for CHIP-associated CVD ([@bib29]). As the inflammatory response can manifest as a complex and dynamic cascade, the timing of treatment with anti-inflammatory therapeutics may be critical. Different cytokines, inflammatory pathways, and hematopoietic lineages may play important roles at different times during the inflammatory response and during CVD and may represent potential therapeutic targets. Presently, these anti-inflammatory agents appear to target mature hematopoietic lineages, but it is intriguing to consider whether HSPCs bearing CHIP-associated mutations could be directly targeted. Our group has shown that inhibition of inflammation can impede the expansion of HSPCs bearing CHIP-associated mutations, suggesting that inflammation also contributes to the pathogenic functions of mutant HSPCs in CHIP ([@bib16]). It is not yet known if blocking the expansion of these mutant HSPCs can ameliorate CHIP-associated CVD. Inhibiting the differentiation and function of specific hematopoietic lineages and targeting aberrant proteins encoded by genes bearing CHIP-associated mutations may also be valuable approaches. For example, the JAK2 inhibitor ruxolitinib effectively inhibits NET formation and decreases thrombosis in mice ([@bib82]), indicating that directly targeting the mutant proteins associated with CHIP may abrogate the altered hematopoietic cell types contributing to CVD.

The clinical relevance of screening CVD patients for CHIP is currently unclear ([@bib46]). If anti-inflammatory agents can prevent CHIP-associated CVD, then screening for CHIP-associated mutations could identify patients who may benefit from prophylactic anti-inflammatory treatment. However, patients presenting with cardiac symptoms likely already have active disease, emphasizing the importance of identifying therapies that can treat existing disease. An important question in understanding the clinical relevance of CHIP-associated CVD is whether it differs from traditional CVD. Screening for CHIP-associated CVD would be most advantageous if it could be used to guide treatment decisions. While current studies indicate that inflammation may be a key mechanism by which CHIP contributes to CVD, inflammation also plays an important role in CVD in general. For example, canakinumab, an antibody against IL-1β, is also efficacious in traditional CVD ([@bib60]). The observation that transplantation of *Tet2*-deficient BM can induce CVD suggests that CHIP-associated mutations may be sufficient to cause CVD in the absence of additional cardiac risk factors ([@bib79]). Larger epidemiological studies are needed to more fully understand the clinical consequences of CHIP-associated CVD, the ways in which it differs from other types of CVD, and the mechanisms by which it interacts with other CVD risk factors. This knowledge will promote the development of therapeutics that can specifically target this patient population.

The screening of specific CHIP-associated mutations may also have significant implications for the clinical manifestation, disease progression, and cell types involved. Understanding the effects of specific mutations may be able to promote a precision medicine approach to treating CHIP-associated CVD in the future. However, as the presence of different comorbidities can also influence CH, the manifestation of CHIP-associated CVD may be affected by these comorbidities ([@bib26]). This possibility may complicate the utility of genetic screening for predicting prognosis and guiding treatment. In considering potential therapies for CHIP-associated CVD, it is important to also consider the ability of these therapies to modulate the leukemic potential of preleukemic HSPCs carrying CHIP-associated mutations. Treatment with anti-inflammatory agents may alter the distribution of cytokines influencing hematopoiesis, potentially modifying the resulting hematopoietic lineages and promoting leukomogenesis. Collectively, these studies indicate the complexities of treating CHIP-associated CVD and underscore the importance of future studies to better understand its pathogenesis and to facilitate the development of novel therapies.

Conclusions {#sec1.9}
-----------

CHIP is a common novel risk factor for both CVD and hematological malignancy. Many unanswered questions remain regarding its underlying mechanisms. Inflammation may play a critical role in the pathogenesis of CHIP-associated CVD; however, additional studies are needed to fully understand its complexity and impact. Furthermore, it is not yet known if inflammation is a common mechanism for CHIP-associated mutations. As many different hematopoietic lineages contribute to CVD, it is likely that CHIP-associated mutations in HSPCs are transmitted to multiple hematopoietic cell types and that these different cell types can influence clinical presentation and disease progression. These differences may be affected by specific CHIP-associated mutations and may have important implications for disease heterogeneity and treatment. Inflammation may also serve as a key link between CVD and hematological malignancy. The relationship between CVD and cancer development in CHIP patients remains unexplored but represents a fascinating new area in cardio-oncology, highlighting compelling links between the CV and hematological systems. Further elucidation of the disease characteristics unique to CHIP-associated CVD will facilitate the discovery of new therapies and improve the clinical care of CHIP patients.
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[^1]: ACE, angiotensin-converting enzyme; *ASXL1*, *Associated sex combs-like 1*; BM, bone marrow; CHIP, clonal hematopoiesis of indeterminate potential; CCL2, C-C motif chemokine ligand 2; *Ccl5*, C-C motif chemokine ligand 5; CXCL1, CXC motif chemokine ligand 1; CXCL2, CXC motif chemokine ligand 2; CXCL3, CXC motif chemokine ligand 3; *DNMT3A*, DNA methyltransferase 3a; *DNMT3B*, DNA methyltransferase 3b; HSPCs, hematopoietic stem and progenitor cells; IgE, immunoglobulin E; IL-1β, interleukin-1β; IL-6, interleukin-6; IL-8, interleukin-8; IL-13, interleukin-13; *JAK2*, Janus-associated kinase 2; *Ldlr*, *low-density lipoprotein receptor*; LPS, lipopolysaccharide; MCP1, monocyte chemoattractant protein 1; NET, neutrophil extracellular trap; NLRP3, NOD-, LRR-, and pyrin domain-containing protein 3; PF-4, platelet factor 4; SHP2, Src homology phosphatase 2; STAT3, signal transducer and activator of transcription 3; *TET2*, Tet methylcytosine dioxygenase 2; TNF-α, tumor necrosis factor-α; VAF, variant allele frequency; N/A, not applicable.
